These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 23318573)

  • 1. Lipid droplet accumulation is associated with an increase in hyperglycemia-induced renal damage: prevention by liver X receptors.
    Kiss E; Kränzlin B; Wagenblaβ K; Bonrouhi M; Thiery J; Gröne E; Nordström V; Teupser D; Gretz N; Malle E; Gröne HJ
    Am J Pathol; 2013 Mar; 182(3):727-41. PubMed ID: 23318573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα.
    Kiss E; Popovic Z; Bedke J; Wang S; Bonrouhi M; Gretz N; Stettner P; Teupser D; Thiery J; Porubsky S; Adams J; Gröne HJ
    Am J Pathol; 2011 Jul; 179(1):92-103. PubMed ID: 21703396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver X receptors preserve renal glomerular integrity under normoglycaemia and in diabetes in mice.
    Patel M; Wang XX; Magomedova L; John R; Rasheed A; Santamaria H; Wang W; Tsai R; Qiu L; Orellana A; Advani A; Levi M; Cummins CL
    Diabetologia; 2014 Feb; 57(2):435-46. PubMed ID: 24201575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes.
    Proctor G; Jiang T; Iwahashi M; Wang Z; Li J; Levi M
    Diabetes; 2006 Sep; 55(9):2502-9. PubMed ID: 16936198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation.
    Zhang C; Shao M; Yang H; Chen L; Yu L; Cong W; Tian H; Zhang F; Cheng P; Jin L; Tan Y; Li X; Cai L; Lu X
    PLoS One; 2013; 8(12):e82275. PubMed ID: 24349242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy.
    Zhang Y; Ma KL; Liu J; Wu Y; Hu ZB; Liu L; Liu BC
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1140-8. PubMed ID: 25921580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy.
    Zhang Y; Ma KL; Liu J; Wu Y; Hu ZB; Liu L; Lu J; Zhang XL; Liu BC
    Acta Diabetol; 2015 Dec; 52(6):1045-56. PubMed ID: 25896009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of LXRs using the synthetic agonist GW3965 represses the production of pro-inflammatory cytokines by murine mast cells.
    Nunomura S; Okayama Y; Matsumoto K; Hashimoto N; Endo-Umeda K; Terui T; Makishima M; Ra C
    Allergol Int; 2015 Sep; 64 Suppl():S11-7. PubMed ID: 26344074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Liver X receptors in the heart leads to accumulation of intracellular lipids and attenuation of ischemia-reperfusion injury.
    Lei P; Baysa A; Nebb HI; Valen G; Skomedal T; Osnes JB; Yang Z; Haugen F
    Basic Res Cardiol; 2013 Jan; 108(1):323. PubMed ID: 23266787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice.
    Spencer MW; Mühlfeld AS; Segerer S; Hudkins KL; Kirk E; LeBoeuf RC; Alpers CE
    Am J Nephrol; 2004; 24(1):20-31. PubMed ID: 14671436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
    Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.
    Chow F; Ozols E; Nikolic-Paterson DJ; Atkins RC; Tesch GH
    Kidney Int; 2004 Jan; 65(1):116-28. PubMed ID: 14675042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver X receptor modulates diabetic retinopathy outcome in a mouse model of streptozotocin-induced diabetes.
    Hazra S; Rasheed A; Bhatwadekar A; Wang X; Shaw LC; Patel M; Caballero S; Magomedova L; Solis N; Yan Y; Wang W; Thinschmidt JS; Verma A; Li Q; Levi M; Cummins CL; Grant MB
    Diabetes; 2012 Dec; 61(12):3270-9. PubMed ID: 22891211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aryl Hydrocarbon Receptor Deficiency Attenuates Oxidative Stress-Related Mesangial Cell Activation and Macrophage Infiltration and Extracellular Matrix Accumulation in Diabetic Nephropathy.
    Lee WJ; Liu SH; Chiang CK; Lin SY; Liang KW; Chen CH; Tien HR; Chen PH; Wu JP; Tsai YC; Lai DW; Chang YC; Sheu WH; Sheu ML
    Antioxid Redox Signal; 2016 Feb; 24(4):217-231. PubMed ID: 26415004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy.
    Tachibana H; Ogawa D; Matsushita Y; Bruemmer D; Wada J; Teshigawara S; Eguchi J; Sato-Horiguchi C; Uchida HA; Shikata K; Makino H
    J Am Soc Nephrol; 2012 Nov; 23(11):1835-46. PubMed ID: 23085633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model.
    Wang XX; Jiang T; Shen Y; Caldas Y; Miyazaki-Anzai S; Santamaria H; Urbanek C; Solis N; Scherzer P; Lewis L; Gonzalez FJ; Adorini L; Pruzanski M; Kopp JB; Verlander JW; Levi M
    Diabetes; 2010 Nov; 59(11):2916-27. PubMed ID: 20699418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver X receptor agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice.
    He Q; Pu J; Yuan A; Yao T; Ying X; Zhao Y; Xu L; Tong H; He B
    Cardiovasc Diabetol; 2014 Nov; 13():149. PubMed ID: 25416469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of macrophage colony-stimulating factor (M-CSF) on the progression of lipid-induced nephrotoxicity in diabetic nephropathy.
    Utsunomiya K; Ohta H; Kurata H; Tajima N; Isogai Y
    J Diabetes Complications; 1995; 9(4):292-5. PubMed ID: 8573750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis.
    Mohamed R; Jayakumar C; Chen F; Fulton D; Stepp D; Gansevoort RT; Ramesh G
    J Am Soc Nephrol; 2016 Mar; 27(3):745-65. PubMed ID: 26334030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation.
    Sorrentino R; Morello S; Chen S; Bonavita E; Pinto A
    J Cell Physiol; 2010 Apr; 223(1):158-67. PubMed ID: 20049870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.